Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Claritin, Linens Make Strange Bedfellows But Licensing Revenue For Merck

This article was originally published in The Tan Sheet

Executive Summary

Merck has a strategy for squeezing more juice out of an OTC brand in an increasingly competitive market segment: out-licensing to non-drug products

You may also be interested in...

Perrigo Gains Pole Position In Private-Label Allegra Race

Perrigo cuts to the front of the queue for launching private-label versions of OTC Allegra, acquiring from Teva the exclusive U.S. sales and distribution rights to generic equivalents of the allergy drug

Claritin 12-Hour Takes Aim At Shorter-Duration Allergy Drugs

Schering-Plough extends the Claritin line into the 12-hour allergy relief niche to go after first-generation antihistamines with shorter durations

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts